echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > With $60 million in financing, can the company launch its first antifellar drug in 20 years?

    With $60 million in financing, can the company launch its first antifellar drug in 20 years?

    • Last Update: 2020-09-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Although severe systemic fungal infections are rare, a growing body of research shows that fungal tolerance to drugs is increasing.
    invasive fungal infections are an important cause of death in patients with HIV infections, tumors, and damaged immunity such as organ transplants.
    , on the other hand, there have been no new drugs in the antifungal field since the first echinocrine drugs were approved 20 years ago.
    This is mainly because, unlike bacteria, fungi are funnel organisms, and many potential targets that are critical to fungal growth or reproduction have similar effects to humans and therefore cannot actually be used as drug targets.
    F2G has discovered and developed a new antifectant called orotomides, which selectively targets the fungus dihydroclic acid dehydrogenase (DHODH), which is lethal to a wide range of rare and drug-resistant fungal infections.
    F2G's first drug candidate, ololofim (F901318), is currently in the clinical phase 2b open label phase for the treatment of rare and drug-resistant invasive fungal infections, such as invasive cryptobacteria (including resistant strains of pyridoxine), cedococcal disease, refilm spores, sickle disease, membrane cystic disease and spores (glycosis).
    , the European Medicines Agency has granted olorofim orphan drugs for the treatment of invasive asmycin and spore worm disease.
    year, the FDA also awarded olorofim breakthrough therapy, making it the first antifellar drug to be recognized as a breakthrough therapy.
    molecular structure of Olorofim (Photo: F2G website) Pathogenic microorganisms have been one of the factors that endanger our health, and with the extensive use of antimicrobials, the resistance of pathogenic microorganisms has increased rapidly worldwide.
    years, multi-drug-resistant bacteria, wide-ranging drug-resistant bacteria, pan-resistant bacteria continue to appear, the market for new antimicrobials, especially new broad-spectrum antimicrobials demand has not been met.
    the FDA has also approved a variety of new antibiotics in recent years, including Sulopenem of Itrum Threapeutics, Eravacycline of Tetraphase Pharmaceuticals and Recarbrio of Merca East.
    same time, large multinational pharmaceutical companies are actively expanding, and in May, Amlyx in San Diego announced a $93 million round of C financing from Pfizer to advance the second phase of its broad-spectrum antifulgic drug fosmanogepix (APX001).
    academic community is also actively applying AI, genomics and other new technologies to explore ways to discover new antimicrobial drugs, many high-quality projects eventually set up companies to promote the commercialization of projects.
    F2G, which has just been financed, is a new company that has left the University of Manchester.
    we look forward to more new antimicrobials in the future, driven by capital.
    : s1. F2G Closes US$60.8 Million Financing to fund late stage development of novel mechanism antifungal agent. Retrived August 12, 2020, from.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.